Search research articles
Contact Us
Filters
Showing results (31-40 of 54) with videos related to
Page
of 6
Sort By:
Cancer Research
|
May 25, 2019
Differential Activity of ATR and WEE1 Inhibitors in a Highly Sensitive Subpopulation of DLBCL Linked to Replication Stress
Lucy A Young, Lenka Oplustil O'Connor, Christelle de Renty, et al.
International Journal of Cancer
|
August 9, 2016
Anti-tumor activity of the ATR inhibitor AZD6738 in HER2 positive breast cancer cells
Hee-Jun Kim, Ahrum Min, Seock-Ah Im, et al.
Molecular Cell
|
September 14, 2010
Rictor forms a complex with Cullin-1 to promote SGK1 ubiquitination and destruction
Daming Gao, Lixin Wan, Hiroyuki Inuzuka, et al.
Virchows Archiv : an International Journal of Pathology
|
January 29, 2013
Validation of the BRCA1 antibody MS110 and the utility of BRCA1 as a patient selection biomarker in immunohistochemical analysis of breast and ovarian tumours
Roy Milner, Helen Wombwell, Sonia Eckersley, et al.
British Journal of Cancer
|
December 19, 2020
SLFN11 informs on standard of care and novel treatments in a wide range of cancer models
Claudia Winkler, Joshua Armenia, Gemma N Jones, et al.
The New England Journal of Medicine
|
June 26, 2009
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers
Peter C Fong, David S Boss, Timothy A Yap, et al.
Molecular Cancer Therapeutics
|
February 1, 2017
AZD6738, A Novel Oral Inhibitor of ATR, Induces Synthetic Lethality with ATM Deficiency in Gastric Cancer Cells
Ahrum Min, Seock-Ah Im, Hyemin Jang, et al.
British Journal of Cancer
|
March 31, 2026
Phase 1 study of ceralasertib, an ATR kinase inhibitor, in combination with durvalumab in patients with recurrent or metastatic NSCLC or HNSCC
Juanita S Lopez, Kevin J Harrington, Seock-Ah Im, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 19, 2008
Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin
Bastiaan Evers, Rinske Drost, Eva Schut, et al.
Cancer Discovery
|
October 30, 2012
Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors
Janneke E Jaspers, Ariena Kersbergen, Ute Boon, et al.
Page
of 6
Search research articles
Search
Showing results (31-40 of 54) with videos related to
Sort By:
Page
of 6
Cancer Research
|
May 25, 2019
Differential Activity of ATR and WEE1 Inhibitors in a Highly Sensitive Subpopulation of DLBCL Linked to Replication Stress
Lucy A Young, Lenka Oplustil O'Connor, Christelle de Renty, et al.
International Journal of Cancer
|
August 9, 2016
Anti-tumor activity of the ATR inhibitor AZD6738 in HER2 positive breast cancer cells
Hee-Jun Kim, Ahrum Min, Seock-Ah Im, et al.
Molecular Cell
|
September 14, 2010
Rictor forms a complex with Cullin-1 to promote SGK1 ubiquitination and destruction
Daming Gao, Lixin Wan, Hiroyuki Inuzuka, et al.
Virchows Archiv : an International Journal of Pathology
|
January 29, 2013
Validation of the BRCA1 antibody MS110 and the utility of BRCA1 as a patient selection biomarker in immunohistochemical analysis of breast and ovarian tumours
Roy Milner, Helen Wombwell, Sonia Eckersley, et al.
British Journal of Cancer
|
December 19, 2020
SLFN11 informs on standard of care and novel treatments in a wide range of cancer models
Claudia Winkler, Joshua Armenia, Gemma N Jones, et al.
The New England Journal of Medicine
|
June 26, 2009
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers
Peter C Fong, David S Boss, Timothy A Yap, et al.
Molecular Cancer Therapeutics
|
February 1, 2017
AZD6738, A Novel Oral Inhibitor of ATR, Induces Synthetic Lethality with ATM Deficiency in Gastric Cancer Cells
Ahrum Min, Seock-Ah Im, Hyemin Jang, et al.
British Journal of Cancer
|
March 31, 2026
Phase 1 study of ceralasertib, an ATR kinase inhibitor, in combination with durvalumab in patients with recurrent or metastatic NSCLC or HNSCC
Juanita S Lopez, Kevin J Harrington, Seock-Ah Im, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 19, 2008
Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin
Bastiaan Evers, Rinske Drost, Eva Schut, et al.
Cancer Discovery
|
October 30, 2012
Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors
Janneke E Jaspers, Ariena Kersbergen, Ute Boon, et al.
Page
of 6